How much funding has Boundless Bio raised?

Boundless Bio has raised $251.4M in total funding, most recently a Series C round.

Who are Boundless Bio's investors?

Boundless Bio's investors include Leaps by Bayer, RA Capital Management, Alexandria Venture Investments, ARCH Venture Partners, Fidelity Management.

When was Boundless Bio founded?

Boundless Bio was founded in 2018.

Where is Boundless Bio headquartered?

Boundless Bio is headquartered in San Diego, California, United States.

What industry is Boundless Bio in?

Boundless Bio operates in Biotech, Healthcare.

How many employees does Boundless Bio have?

Boundless Bio has 11-50 employees.

Boundless Bio

IPO

Unlocking a New Paradigm in Cancer Therapeutics

San Diego, United States · Founded 2018 · $251.4M raised

Biotech

Healthcare

Headquarters: San Diego, California
Employees: 11–50
Founded: 2018
Business Model: B2B

Website: boundlessbio.com
Total Funding: $251.4M
Last Round: $100.0M Series CMay 2023
Rounds: 3

About

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in over 17% of cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality and develops small molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit cancer cell growth and resistance.

Summary

Boundless Bio is a Biotech company based in San Diego, United States, founded in 2018. It has raised $251.4M in total across 3 rounds, most recently a $100.0M Series C round in May 2023. Investors include Leaps by Bayer, RA Capital Management and Alexandria Venture Investments.

LinkedIn X (Twitter)